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Abstract
Prostate is an immune-competent organ normally populated by inflammatory cells. Prostatic inflammation origin
can be multi-factorial and there are some emerging evidences on its possible role as a factor involved in prostate
cancer (PC) pathogenesis and progression.
This review critically analyzes the role of inflammation as a prognostic factor for progression and aggressiveness of
PC. We verified the last 10 years literature data on the association between inflammation and PC aggressiveness, or
PC response to therapies.
Several studies tried to correlate different inflammatory factors with the aggressiveness and metastatization of PC;
all data sustain the role of inflammation in PC progression but they also produce confusion to identify a reliable
clinical prognostic marker.
Data on patients submitted to radical prostatectomy (RP) showed that cases with marked intraprostatic tissue
inflammation are associated with higher rate of biochemical progression; systemic inflammation markers appear to
have a significant prognostic value.
Analyzing data on patients submitted to radiotherapy (RT) emerges a significant association between high
neuthrophil to lymphocyte ratio (NLR) and decreased progression free survival and overall survival; also plateled to
lymphocyte ratio (PLR) and C-reactive protein (CRP) have been proposed as significant prognostic factors for
progression and overall survival.
In patients submitted to androgen deprivation therapy (ADT), inflammation may drive castration resistant PC (CRPC)
development by activation of STAT3 in PC cells. NLR has been proposed as independent predictor of overall
survival in CRPC submitted to chemotherapy.
Most of data are focused on markers related to systemic inflammation such as NLR and CRP, more than specifically
to chronic prostatic inflammation. The suggestion is that these inflammatory parameters, also if not specific for
prostatic inflammation and possibly influenced by several factors other than PC, can integrate with established
prognostic factors.
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Background
Inflammation and prostate cancer: which evidences?
The prostate is an immune-competent organ and is
normally populated by a small number of inflammatory
cells [1]. In particular regulatory T-cells are mainly lo-
cated in the fibromuscular stroma and in the peri-
glandular area [2]. The origin of prostatic inflammation
can be multifactorial, including bacterial infections,
viruses, dietary factors, hormones, autoimmune re-
sponses and urine reflux [1, 3].
The persistence of some of these factors can consti-
tute to chronic prostatic inflammation. Prostate can-
cer (PC) is now the most common cancer among
men. The role of infection or inflammation is sus-
tained in different cancer sites and also in PC. Epide-
miologic, histo-pathologic and molecular pathologic
studies provide the emerging evidence of the possible
role of prostatic inflammation as a factor involved in
PC initiation and/or progression [4–6]. Inflammation
can play a role in PC carcinogenesis through several
mechanisms: causing cellular and genomic damage;
promoting cellular turnover; creating a tissue micro-
environment inducing cell replication, angiogenesis
and tissue repair [4, 7].
The high prevalence of chronic inflammation in patho-
logical samples of prostate tissue from surgery or pros-
tate biopsy has sustained a possible link between chronic
inflammation and PC [8, 9]. Pro-inflammatory cytokines,
inflammatory mediators and growth factors related to
inflammation can determine uncontrolled proliferative
response, rapidly dividing cells more likely to undergo
mutation, as observed in cancer [7, 10]. Several PC sus-
ceptibility genes such as RNASEL, MSR1,MIC1 involved
in PC carcinogenesis, encode proteins with functions in
response to inflammation, infection and oxidative stress:
their mutation may reduce the possibility of preventing
carcinogenesis through these pathways [4, 11]. Some
data show that chronic inflammation can induce prolif-
erative events and post-translational DNA modifications
in prostate tissue also through oxidative stress [8, 12].
Repeated tissue damage and oxidative stress related to
this event may produce compensatory cellular prolifera-
tion with the risk of hyperplastic growth or neoplastic
transformation [13]. It is accepted that prostatic inflam-
mation can generate free radicals such as nitric oxide
that can be converted by cyclo-oxigenase enzymes to
different eicosanoids and prostaglandins that have been
recognized as regulator of prostate cell proliferation
[14]. Normally glutathione transferase activity defends
prostate cells against the genomic damage induced by
oxidants isolated at sites of inflammation [8]. The
methylation of this gene produce the loss of his protect-
ive activity and it could be implicated in the translation
from inflammation to pre-neoplastic lesions such as high
grade prostatic intraepithelial neoplasia (PIN) and there-
fore to PC [14].
As clinical data, a 5-year follow-up study based on
prostate biopsies established that chronic inflammation
accounts for nearly 20% PC development [15, 16]. More-
over, inflammatory atrophy was found in about 40% of
PC cores in that study. Observations from many lines of
research indicate the existence of role of inflammation
in prostate carcinogenesis and progression [17].
Aim
The aim of the present review is to critically analyze the
role of prostatic inflammation as a prognostic factor for
the progression and aggressiveness of PC. In particular,
we did not analyze the relationship between inflamma-
tion and PC development or incidence but, we verified
data on the association between inflammation and PC
aggressiveness, or PC response to therapies.
Our aim is to analyze whether, in cases with PC diag-
nosis, an association with an inflammatory status may
determine a poorer prognosis, higher aggressiveness of
the tumor and lower response to therapies. We also try
to verify a possible role of prostatic inflammation as a
prognostic factor in PC patients, for tumor progression
despite surgical, radiotherapic or medical therapies.
Methods
We searched in the Medline and Cochrane Library data-
bases (primary fields: prostate neoplasm and inflamma-
tion; secondary fields: aggressiveness, Gleason score,
prognostic, radical prostatectomy, radiation therapy, an-
drogen deprivation therapy, CRPC without language re-
striction from the literature of the last 10 years. We
included original articles, clinical trials conducted in
humans and reviews.
Our review was divided in different sections analyzing
the following items: relationship between inflammation
and PC aggressiveness; influence of inflammation on the
response to surgery, radiotherapy, androgen deprivation
therapies; role of inflammation in CRPC. At the end of
each section we critically analyzed data in terms of a
possible prognostic role of prostatic inflammation in
these specific settings.
Results and discussion
Inflammation and prostate cancer aggressiveness
Different clinical and pathological parameters and clas-
sifications are used to determine PC aggressiveness and
risk of progression. In particular the Gleason grading is
used in conjunction with other clinical and molecular
variables, including serum prostate specific antigen
(PSA) levels and clinical stage, to classify PC in risk
classes of progression and to help make treatment deci-
sions for PC.
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PC is one of the most common causes of cancer-
related deaths among males; however a significant per-
centage of diagnosed PC have a relatively indolent form
that is unlikely to progress with time. A subset of PC, on
the contrary, exhibit aggressive properties, such as rapid
proliferation, metastatic spread, resistance to therapies.
To obtain a correct management of PC, the major chal-
lenge remains to distinguish patients who need definitive
treatments from cases who have a latent tumor.
Gurel et al. [18], histologically examined prostate bi-
opsy samples for inflammation using the United States
National Institute of Health consensus grading system.
Cases with inflammation in ≥ 1 biopsy core were 1.78
times (95% CI 1.04–3.06) more likely to develop PC in
the core examined in the biopsy than those who had no
evidence of inflammation.
This association was more pronounced for high grade
tumors (Gleason sum 7–10; OR 2.24, 95% CI 1.06–4.71)
than for low grade cases (Gleason sum 6; OR 1.57,95%
CI 0.83–300) [18].
From the placebo arm of the Prostate Cancer Preven-
tion Trial, Gurel et al. [18] showed a significant associ-
ation between the presence and extent of chronic
inflammation in prostate biopsy cores and high grade
PC (Gleason sum 7–10; OR-2.24;95% CI 1.06–4.71) but
not in low grade cases (Gleason sum 6; OR 1.57; 95% CI
0.83–3.0).
Adaptive immune cells
As adaptive immune cells, analysis of two major prostate
tumor-infiltrating lymphocyte subsets showed that cap-
sular and perineural invasion as well as biochemical pro-
gression was related to strong infiltration of T and B
lymphocytes [15, 19]. Mc Ardle et al. [20] showed that
the presence of increase CD4+ T-lymphocyte infiltrate
was associated with poor PC prognosis and it can pre-
dict survival.
Ammirate et al. [21] found that PC progression and
metastasis is associated with inflammatory infiltration
of macrophages and lymphocytes and activation of I
kappaB kinase (IKK) by an NF-kappaB independent
mechanism.
Davidsson et al. [22] in a case control study on cases
diagnosed for PC, showed that men with greater num-
bers of CD4+ regulatory lymphocytes in their PC envir-
onment have an increased risk of dying of PC and this
identification may predict clinically relevant tumors.
Although the role of B-lymphocytes in cancer has
been overshadowed by the interest in T-cell responses,
B-cells can play a complementary role in the immune
response against tumor [15]. Gannon et al. [23] com-
pared metastatic and non-metastatic pelvic lymph
nodes from PC cases and controls. They found a de-
creased presence of CD20+ B-lymphocytes and CD38+
lymphocytes in metastatic lymph nodes comparatively
to control lymphnodes.
Recently neutrophil-to-lymphocyte ratio (NLR), an
inflammatory parameter, has been reported to be of
prognostic value in some solid tumors including PC
[24]. Yin et al. [24] conducted a meta-analysis to obtain
a reliable assessment of the prognostic significance of
NLR calculated from the white blood cell differentiated
counts in PC patients. A total of 14 studies were in-
cluded and they showed that elevated NLR was not sig-
nificantly associated with the poor overall survival (OS)
(HR 1.45; 95% CI 0.77–2.71; p = 0.248) or recurrence-
free survival (HR = 1.34; 95% CI 0.89–2.02; p = 0.155) of
patients with localized PC. On the contrary elevated
NLR predicted poorer OS (HR 1.57, 95% CI 1.41–1.74;
p < 0.001) and progression-free survival (HR = 1.97;95%
CI 1.28–3.04; p = 0.002) in metastatic PC. This finding
was also confirmed in a second meta-analysis on 9418
PC patients from Tang et al. [25]. In the majority of
studies, NLR was not significantly associated with Gleason
grading in PC patients (p = 0.573) [25, 26].
Innate immune cells
Various innate immune cells have been involved in PC
progression. Macrophages are a source of secreted pro-
inflammatory cytokines and they are distinguished in
two phenotypes: M1 with tumor inhibitor properties
and M2 with tumor stimulatory properties [15, 27, 28].
Lanciotti et al. [28] showed that a high density of mac-
rophages in PC is associated with more aggressiveness
and poorer prognosis. In particular M2 phenotype was
more presented in Gleason score 8–10 and pT3a stage.
As showed by Fang et al. [29] in co-cultured prostate
epithelial cells, M2 induction of aggressiveness involved
the alteration of signaling of macrophage, androgen recep-
tor (AR), inflammatory chemokine CCL4-STATE3 activa-
tion, down regulation of p53/PTEN tumor suppressors.
Chemokines
Besides immune cells, chemokine receptors have been
shown highly expressed on tumor cells in comparison to
normal glands [15] and evidences have been provided
that chemokines are involved in the metastatization and
progression of different tumors. In vivo based studies on
chemokines in PC have been focused on CXCL8,
CXCL12 and CCL2 [30–32]. Chemokines can facilitate
tumor progression and dissemination either by shaping
the functional profile of infiltrating lymphocytes or by
activating stromal and neoplastic cells [15]. Changes in
chemokine receptors may be necessary to activate tumor
progressing signals. For example, more aggressive PC
cells express higher levels of CCR2 compared with less
aggressive cells and they increase also in metastatic com-
pared to localized PC [33]. Moreover increased serum
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levels of CXCL8 and CCL2 have been associated as pos-
sible prognostic markers of a high grade and progressive
PC [34, 35].
Cytokines
Multiple inflammatory cytokines have been identified as
potential mediators between prostatic inflammation and
PC risk and aggressiveness [36]. One of these is macro-
phage inhibitory cytokine 1 (MIC-1), a member of the
transforming growth factor beta family. Some evidence
suggested an up regulation of MIC-1 related to PC ag-
gressiveness and that circulating levels of MIC-1 can
predict poor prognosis for PC [37]. IL-6 is a multifunc-
tional cytokine which is expressed in most PC cell lines
and the expression is at higher levels in those which do
not express the androgen receptor (AR) and show an en-
hanced malignant potential [38]. Aberrant IL-6 signal
transducer and activator of transcription-3 (STAT3) sig-
nalling and loss of p53 occur during PC progression to
metastatic disease [39].
Neveu et al. [40], in primary prostate cell culture from
patients submitted to radical prostatectomy, showed that
the baseline IL-8 secretion level was associated with PC
aggressiveness and the median baseline IL-8 levels were
significantly lower in cases with non-aggressive PC com-
pared to those having aggressive PC (p = 00005). In par-
ticular the Gleason score significantly increased with the
basal level of IL-8 (rho =0.63; p = 0.0007).
Some studies reported on the association between one
or multiple single nucleotide polymorphism (SNP) in
inflammation-related pathways and prostate cancer risk
and aggressiveness [36, 41]. Zabaleta et al. [42] evaluated
15 SNP in five cytokine genes (IL-1B,IL-10, TNF alfa, IL-
6 and IL-8) in relation to risk of aggressive PC (Gleason
score ≥ 8 and PSA > 20 ng/ml) and they found an associ-
ation between aggressive PC and an IL-8 (IL-8-47CT)
genotype (OR = 3.5;95% CI 1.13–10.88), as well as an in-
creased risk with combined genotypes in IL-1B and IL-
10 (OR = 3.38;95% CI 1.70–6.71).
SUMO-specific protease 1 (SENP1) is a member of
the SUMOylation protease family and has a crucial
role in the regulation of androgen receptor (AR)
dependent transcription and inflammatory hypoxia
signaling [43]. Wang et al. [43] analyzed 150 human
PC specimens and they showed that SENP1 expres-
sion directly correlates with PC aggressiveness. In fact
higher SENP1 scores corresponded with higher Gleason
scores of PC patients. Moreover, silencing SENP1 level in
metastatic PC cells, perturbs their ability to metastatize to
the bone [43].
Fucosylation haptoglobin (Fuc-Hpt) is an important
oligosaccharide modification associated with inflamma-
tion and cancer. Fujita et al. [44] in 98 PC cases submit-
ted to radical prostatectomy showed that serum levels of
Fuc-Hpt were significantly associated with Gleason score
P < 0.01) and Fuc-Hpt levels were significantly higher in
patients with Gleason score ≥ 7 than in those with Gleason
score 6. Authors proposed Fuc-Hpt serum determination
as a novel PC biomarker for predicting aggressiveness and
prognosis [44].
Another important cytokine involved in PC progres-
sion appears to be the macrophage migration inhibitory
factor (MIF) [45]. Tawdros et al. [46] showed that an in-
creased extracellular release in MIF induces neuroendro-
crine (NED) differentiation in PC stimulating an AR
independent progression. The relevance of this study is
to link MIF release in chronic prostatic inflammation, to
the development of an aggressive phenotype such as
NED in PC.
Recently, an emerging class of inflammasomes is con-
sidered as master regulators of inflammation. Inflam-
masomes are a group of multimeric proteins that
consist of NLR protein, an apoptosis-associated speck-
like protein containing a carboxyterminal CARD
(ASC), and procaspase-1 [47]. Assembly of inflamma-
somes complex activates caspase-1 leading to the secre-
tion and the maturation of proinflammatory cytokines
IL-1 and IL-18, which causes a wide variety of bio-
logical effects associated with infections. NLRP3 is one
of the most studied inflammasomes and senses patho-
gens and danger signals in response to injury or infec-
tion. Therefore, various stimuli such as urine reflux,
uric acid crystals, bacteria, or fungi may lead to activa-
tion of inflammasome-medicated proinflammatory cy-
tokines in the prostate driving tumor development [47].
Mast cells
MCs (MCs) are recognized as important effectors in
Immunoglobulin-E (Ig-E) associated immune responses,
and potent effector cells of the innate immune system
[48]. In some tumor settings MCs have a protective role,
exerted by their proinflammatory mediators, while in
other tumors MCs may directly influence the advance-
ment of the cancer cells by stimulating the neovascular-
ity, tissue remodeling and modulation of the host
immune response [48]. In PC, MCs have been only re-
cently indicated as potential independent prognostic
marker and MCs targeting associated with castration
suggested as a potential therapy. Xie et al., in vitro and
in vivo models, [49] demonstrated that PCa cells may
have better capacity than normal prostate to recruit
mast cells and infiltrating mast cells could enhance PCa
resistance to chemotherapy and radiotherapy via activa-
tion of p38/p53/p21 and ATM protein kinase signals.
Critical analysis
Several studies in the literature tried to correlate differ-
ent inflammatory factors with the aggressiveness and
Sciarra et al. Journal of Inflammation  (2016) 13:35 Page 4 of 11
metastatization of PC. Innate and adaptive immune cells,
chemokines and cytokines, all showed to significantly
correlate to PC aggressiveness (Table 1). These data to-
gether confirm the role of inflammation in PC progres-
sion but they also produce confusion to identify a
reliable clinical prognostic marker. However, innate and
adaptive immunity cells may play a dichotomous role,
acting in the context of both pro-tumorigenic and anti-
tumorigenic depending on the stage of disease, type of
inflammation, and/or the tumor microenvironment [6].
Some of these factors can be detected only on prostate
tissue samples, others have been suggested as serum
markers. NLR can be simply obtained in the clinical
practice and it is presented in several studies as a strong
indicator of PC prognosis and risk of progression in
metastatic cases. Its role seems to be independent to the
Gleason score of the tumor.
Among Inflammatory cytokines, MIC-1, IL-6 and IL-8
may be prognostic markers of aggressiveness and meta-
static progression but data on their serum determination
remain limited. MCs have been recently indicated as
novel independent prognostic markers in PC, although
previous studies on prostatic biopsies associated high
MC densities with favorable tumor characteristics and
good prognosis. An explanation for these appearing to
be a discrepant finding remains the observation that PC
is a multifocal and heterogeneous disease [48, 49].
The potential mechanistic relationships between the
molecular events associated with the persistent inflam-
matory response and prostate carcinogenesis have im-
portant implications for optimizing the current therapies
against different prostatic disorders and PC [50].
Prognostic value of inflammation in prostate
cancer submitted to radical prostatectomy
Radical prostatectomy (RP) is the main treatment choice
for localized PC. Risk of biochemical and clinical pro-
gression is related to different clinical parameters such
as Gleason score, preoperative PSA, pathological staging.
Currently, RP is the only treatment for localized PC able
to show a benefit for OS and cancer-specific survival
(CSS), compared with conservative management, as
shown in one prospective randomized trial [51].
Preoperative models for PC risk stratification include
D’Amico or Partin tables and they are based on initial
PSA values, biopsy Gleason score and clinical T stage.
Klink et al. [52] analyzed 287 men with PC submitted
to RP to explore the association between tumor inflam-
mation, adverse pathology and biochemical progression
after surgery. Mild and marked inflammation was found
in 53 and 30% of tissue samples respectively. Cases with
marked inflammation were significantly more likely to
have higher clinical stage, higher PSA, higher percent
of cores positive and positive margins. On univariate
analysis, increasing inflammation grade was associated
with progressively higher risk of positive margins (OR
2.26–3.56), capsular penetration (OR 3.12–3.19), sem-
inal vesicle invasion (OR 4.08–6.83). After adjusting for
multiple clinical characteristics, higher grade of inflam-
mation remained significantly associated with risk of
capsular penetration, positive margins and seminal
vesicle invasion. Overall, increasing inflammation grade
was associated with biochemical progression (p = 0.02).
Mild and marked inflammation were associated with
2.18 (95% CI 1.16–4.14) and 2.55 (95% CI 1.31–
4.97)—fold greater biochemical progression rate versus
no inflammation. However the association of inflamma-
tion with biochemical progression rate did not reach
statistical significance (P > 0.2) after adjustment with
the other clinical parameters.
Systemic inflammation is a host reaction to carcino-
genesis or cancer progression and serum levels of butyr-
ylcholinesterase (BChE) have been reported to reflect
the presence of inflammation and other clinical condi-
tions [53]. Serum levels of BChE has been found to de-
crease during inflammation. Koie et al. [54] in a
retrospective study reviewed the pathological records
of 535 PC patients submitted to RP. The cut-off point
for the serum BChE level was determined as 168 IU/L
according to previously described methods. Biochem-
ical progression free survival rates were 77.7% in
BChE ≥ 168 IU/L (95% CI 115.2–152.2) and 55.0% in
BChE < 168 IU/L (95% CI 104.4–131.7; p < 0.001). On
multivariate analysis, initial PSA and serum BChE
levels were independent significant predictors of bio-
chemical progression.
Table 1 OR and 95% CI values for the association between different inflammatory parameters and PC aggressiveness
Parameter Reference Study characteristics Association OR (95% CI) P value
Histological prostatic inflammation [17] Phase II study on prostate biopsies Inflammation and high grade PC 2.24 (1.06–4.71) <0.01
Histological prostatic inflammation [17] Prostate cancer prevention
trial on prostate biopsy
Inflammation and high grade
(Gleason score 7–10) PC
2.24 (1.06–4.71) <0.01
Serum NLR [26] metanalysis NLR and high grade PC – 0.573
Serum SNP [41] Phase II study IL-8 and high grade PC 3.5 (1.13–10.88) <0.01
Serum SNP [41] Phase II study IL-1B and IL-10 3.38 (1.70–6.71) <0.01
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Shafique et al. [55] investigated the role of
inflammation-based prognostic scores, the modified
Glasgow Prognostic Score (mGPS) and neutrophil-
lymphocyte ratio (NLR), to predict progression after RP.
The mGPS was constructed by combining C-reactive
protein and albumin whereas NLR by calculating the ra-
tio of neutrophils to lymphocytes. Systemic inflamma-
tion appeared to have significant prognostic value. The
mGPS predicted poorer 5-year overall survival inde-
pendent to age, PC grade and NLR. Raised mGPS had a
significant association with excess risk of death (OR
2.41; 95% CI 1.37–4.23) among aggressive, clinical sig-
nificant PC.
Critical analysis
Data on a possible prognostic role of prostatic inflamma-
tion in the clinical response to RP in PC are limited in
the literature (Table 2). As of now, the studies are mainly
retrospective, but some findings may suggest that the
grade of inflammation in preoperative biopsy specimens
could be used to risk-stratify men with PC for risk of
biochemical progression after RP [54, 55]. However, in a
multivariate analysis after adjustment with the other
clinical parameters (PSA, clinical stage, Gleason score),
inflammation did not result an independent predictor.
The suggestion that serum markers of systemic inflam-
mation may be independently related to the biochemical
progression free survival must be confirmed in prospect-
ive studies.
Prognostic value of inflammation in prostate
cancer treated by radiotherapy
Definitive radiotherapy is a treatment option for local-
ized or locally advanced PC. Clinical parameters related
to treatment response and risk of progression are serum
PSA, clinical T stage and biopsy Gleason score.
The results of the Glasgow Inflammation Outcome
Study [56, 57] demonstrated that an increased neuthro-
phil-to-lymphocyte ratio (NLR) had a prognostic value
in localized PC. However the study included a rather
heterogeneous population of PC patients. Langsenleh-
ner et al. [58] analyzed 415 consecutive patients with
histologically confirmed PC who underwent radiation
therapy. Based on previous data, a NLR cutoff of 5
was applied to differentiate between low (<5) and
high (≥5) NLR and it was evaluated before the radio-
therapy. A significant association between high NLR
and decreased progression free survival (p = 0.015)
and decreased overall survival (p = 0.011) was found.
Both univariate and multivariate analysis showed that
elevated NLR was associated with decreased clinical
progression free survival (HR 3.09; 95% CI 1.64–5.82
p < 0.001) and decreased overall survival (HR 2.16;
95% CI 1.17–3.99; p = 0.013). The prognostic value of
NLR remained significant also after adjustment for
other clinical parameters such as Gleason score and
clinical stage. Bahig et al. [59] retrospectively analyzed
950 PC cases submitted to radiotherapy for localized
disease. Neutrophil count (median 4.5 × 103/μl, range
0.9–12) (HR =1.18;95% CI 1.01–1.37,p = 0.028) but
not NLR (median 3.0, range 0.1–18.4) was associated
to overall survival.
Also plateled-to-lymphocyte ratio (PLR) which is cal-
culated as the ratio of plateled count to lymphocyte
count has been proposed as an assessable marker of sys-
temic inflammation and has been presented as prognos-
tic marker of different cancers. Langsenlehner et al. [60]
evaluated 374 PC patients treated with external 3D
radiotherapy. The optimal cut-off level for PLR was fixed
at 190. A high PLR was a significant prognostic factor
for metastasis free survival (HR = 2.24 95% CI 1.06–4.76;
p = 0.036), cancer specific survival (HR 3.99;95% CI
1.19–13.4; p = 0.025) and overall survival (HR 1.87;95%
CI 1.02–3.42; p = 0.044) by multivariate analysis. The
prognostic value of PLR remained significant and inde-
pendent also after adjustment for Gleason score and
clinical stage.
Schoenfeld et al. [61] evaluated association between
single nucleotide polymorphisms (SNP) in RNASEL, a
gene implicated in inflammation and clinical response of
434 PC cases submitted to radiotherapy. SNP of
rs12757998 was associated with a significant decreased
risk for biochemical recurrence (HR 0.60; 95% CI 0.40–
0.89; p = 0.02). This association remained significant also
Table 2 OR and 95% CI values of different inflammatory parameters used as prognostic indicators for PC submitted to radical
prostatectomy
Parameter Reference Study characteristics Association OR (95% CI) P value
High grade histological prostatic
inflammation
[47] Phase II study on RP High grade inflammation and
positive surgical margins or
capsular penetration or seminal
vesicle invasion
2.26–3.56 <0.01
3.12–3.19
4.08–6.83
High grade histological prostatic
inflammation
[47] Phase II study on RP High grade inflammation and
biochemical recurrence
2.55 (1.31–4.97) 0.02
Systemic inflammation on mGPS [50] Phase II study on RP mGPS and risk of death 2.41 (1.37–4.23) <0.01
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after adjustment for Gleason score and clinical stage, or
selecting only cases at high risk.
Thurner et al. [62] in 261 PC patients treated with ex-
ternal 3D conformational radiotherapy, analyzed the
prognostic relevance of elevated plasma C-reactive pro-
tein (CRP) as a marker of inflammation. The optimal
cut-off level for CRP was 8.6 mg/l. An elevated CRP
plasma level was associated with decreased cancer spe-
cific survival (HR 3.36; 95% CI 1.42–7.91; p = 0.006) and
overall survival (HR 3.24;95% CI 1.84–5.71; p < 0.001) at
univariate and multivariate analysis. No significant asso-
ciation between CRP and Gleason score or tumor stage
was found (p > 0.05). Using ROC curve analysis, the au-
thors calculated ideal cut-off values of CRP in the three
risk groups at 8.9,8.4 and 13.4 respectively.
Critical analysis
More clinical data on the relationship between inflam-
mation and response to radiotherapy for PC are present
in the literature (Table 3). The populations analyzed are
larger and more homogeneous and data are examined by
multivariate analysis so to define their independent
prognostic value. Markers of systemic inflammation
more than marker specific for prostatic inflammation
have been examined. In particular NLR but also PLR
and CRP showed a significant and independent prognos-
tic value for patients submitted to radiotherapy, either in
terms of clinical progression or of overall survival, also
after adjustment for Gleason score and clinical stage
[59, 60]. In the intermediate and high risk classes as de-
scribed by D’Amico et al., NLR and CRP are able to fur-
thermore stratify cases in terms of clinical progression
free survival [62].
Elevated NLR and CRP levels may reflect increased
concentrations of these pro-inflammatory cytokines that
create a microenvironment favouring PC proliferation
and metastatization despite radiotherapy [62]. Further-
more, raised CRP concentrations may produces in-
creased serum levels of vascular endothelial growth
factor (VEGF) [63, 64]. However NLR, PLR and CRP are
not specific markers of inflammation that might be in-
fluenced by several other conditions such as active infec-
tion, inflammatory diseases and smoking behaviour
independent of PC.
Prognostic value of inflammation in prostate
cancer treated by androgen deprivation therapy
and in castration resistant PC
Androgen deprivation therapy (ADT) can be achieved
by either suppressing the secretion of testicular andro-
gens using a surgical castration via orchiectomy or a
medical castration via inhibiting the hypothalamic pituit-
ary axis using LH-RH agonists or antagonists or inhibit-
ing the action of circulating androgens at the level of
their receptor using competing compounds known as
anti-androgens. In addition, these two methods can be
combined to achieve what is known as complete (or
maximal or total) androgen blockade (CAB).
An in vivo model demonstrated that during ADT infil-
trated of B cells can activate NFkB kinase with the up-
regulation of cytokines such as CXCL-1,IL-8,IL-12,TNF
alpha. These cytokines activates STAT3 in PC cells and
shortens the duration of ADT response promoting
tumor cell survival through anti-apoptotic signaling [21].
These treatments can be involved in the development of
a CRPC [65].
Sharma et al. [66] analyzed 122 metastatic PC cases
treated by ADT and measured in the serum different cy-
tokines such as MCP-1,IL-1,IL-2,IL-6,IL-8 and TNF
alpha. On multivariate analysis only IL-8 (HR 1.9;95% CI
1.0–3.5, p = 0.04) and TNF alpha (HR 2.0;95% CI 1.1–
3.5; p = 0.02) resulted significant and independent pre-
dictors of overall survival during ADT.
Treatment options for CRPC have expanded with the
introduction of several new approved agents including
abiraterone, enzalutamide, radium 233 and different che-
motherapic agents. Docetaxel with prednisone remain
the standard first-line chemotherapy for treatment of
Table 3 OR and 95% CI values of different inflammatory parameters used as prognostic indicators for PC submitted to radiotherapy
Parameter Reference Study characteristics Association OR (95% CI) P value
Systemic inflammation NLR [53] Phase II on radiotherapy
as primary treatment
NLR and clinical progression
free survival or overall survival
3.09 (1.64–5.82) <0.001
2.16 (1.17–3.99) 0.013
Systemic inflammation PLR [55] Phase II study on radiotherapy
as primary treatment
PLR and metastasis free survival
or cancer specific survival or
overall survival
2.24 (1.06–4.76) 0.036
3.99 (1.19–13.4) 0.025
1.87 (1.02–3.42) 0.044
SNP in RNASEL [56] Phase II study on radiotherapy
as primary treatment
SNP of rs12757998 and biochemical
recurrence
0.60 (0.40–0.89) 0.02
Systemic inflammation CRP [57] Phase II study on radiotherapy
as primary treatment
CRP and cancer specific survival
or overall survival
3.36 (1.42–7.91) 0.006
3.24 (1.84–5.71) <0.001
Sciarra et al. Journal of Inflammation  (2016) 13:35 Page 7 of 11
CRPC. Prognostic and predictive biomarkers for re-
sponse to the different agents are urgently needed so to
identify the better therapeutic sequences for each pa-
tient. Inflammation in the prostatic microenvironment
may also drive CRPC development during ADT.
Templeton et al. [67] analyzed in 356 metastatic CRPC
patients submitted to docetaxel the prognostic role of
NLR. In univariate analysis higher performance status,
LDH and NLR (HR 1.65, 95% CI 1.25–2.18; p < 0.001) at
baseline were associated with shorter OS. In multivariate
analysis the highest statistical significance was obtained
when liver metastases, hemoglobin <120 g/L, LDH > 1.2
X ULN and NLR > 3.0 were included in the model.
Similarly Lorente et al. [68] analyzed the prognostic
role of NLR in a phase III study on 755 metastatic CRPC
patients submitted to cabazitaxel as second line chemo-
therapy. Baseline NLR was associated with OS in univar-
iate (HR 2.89;95% CI 2.12–3.94; p < 0.001) and
multivariate analysis (HR 1.91;95% CI 1.31–2.79; p =
0.001) also adjusted for other clinical parameters. Au-
thors selected a NLR cut-off of 3 as the most appropri-
ate. Patients with a <3 NLR level had a statistically
significant higher median OS (15.9 months versus
12.6 months, HR 1.55;95% CI 1.3–1.84; p < 0.001). than
patients with a NLR ≥ 3.
Van Soest et al. [69] used data from two randomized
phase III studies on 2230 men with metastatic CRPC pa-
tients submitted to docetaxel, to investigate the prognos-
tic value of NLR. The optimal threshold of NLR for the
prediction of OS was set a 2.05. In multivariate analysis
both NLR and ADT duration before CRPC patients were
associated with an increased risk of death (NLR HR
1.29;95% CI 1.11–1.50; p < 0.001) after adjustment for
the other clinical parameters. Survival curves showed an
OS of 26 months (95% CI 23.8–27.8) for men with a
NLR < 2.0 and 19.1 months (95% CI 17.7-20.2) for men
with a NLR ≥ 2.0. Sonpavde et al. [70] evaluated the
prognostic impact of NLR as a marker for inflamma-
tory and immune state in men with mCRPC follow-
ing docetaxel. It is shown that NLR may be
associated with an independent poor prognostic im-
pact in post-docetaxel patients with mCRPC (1.55
[1.32, 1.83], P < .001). In particular NLR determin-
ation increased the c-statistic from 0.703 to 0.715 in
a prognostic model that included LDH levels,
hemoglobin, > 1 organ involved by metastatic dis-
ease, alkaline phosphatase, the number of prior cycles
of docetaxel and progression to docetaxel.
Liao et al. [71], in 115 metastatic CRPC patients sub-
mitted to docetaxel, showed that median progression
free survival (9.8 versus 7.5 months; p < 0.001) and OS
(26.5 versus 13.5 months; p = 0.002) were higher in cases
who did not have an elevated CRP than in those with
an elevated CRP. In particular in a multivariate analysis,
patients with a CRP > 8 mg/l were at significantly
higher risk of tumor progression (HR 2.18; 95% CI
1.40–3.40; p = 0.001) and death (HR 2.0; 95% CI 1.28–
3.12; p = 0.002) than patients with a CRP ≤ 8 mg/l.
Expanding on the utility of a single biomarker, the
modified Glasgow Prognostic Score (mGPS) calculated
using CRP and albumin levels, has been identified as a
powerful marker of systemic inflammation [72]. Linton
et al. analyzed the prognostic value of mGPS and NLR
in 220 metastatic CRPC chemotherapy naïve patients
but considered for docetaxel treatment [72]. NLR was
not significantly prognostic for OS (HR 0.98; p =
0.91). On the contrary albumin (HR 0.28; 95% CI
0.14–0.56; p < 0.01) and CRP (HR 1.22; 95% CI 1.0–
1.48; p = 0.048) were independently prognostic for OS.
Combining the two parameters, a statistically signifi-
cant association (p < 0.001) was observed between
mGPS and lower OS (HR 1.87; 95% CI 1.35–2.59)
with a marked decline in survival at higher scores
(median survival 23.5 months at mGPS 0; 9.8 months
at mGPS 2).
Leibowits-Amit et al. [73], in 116 metastatic CRPC pa-
tients treated with abiraterone, showed that NLR is a
significant prognostic factor (OR 0.8; 95% CI 0.6–0.9,p =
0.05) for prediction of PSA progression. Using a NLR
cut-off of 5, at multivariate analysis, a NLR ≤ 5 associ-
ated with restricted metastatic spread remained signifi-
cantly predictor for PSA progression (OR 4.3; 95% CI
1.4–13.3; p = 0.01).
Critical analysis
Systemic inflammation represents a truly novel and un-
explored prognostic variables in CRPC [74], independent
to other clinical parameters such as stage. It does not
substitute but rather integrates with established prog-
nostic factors. Pinato et al. [74] suggested that inflamma-
tion may predict not only survival but also cancer-
related symptomatic burden (association between NLR
and performance status) and risk of chemotherapy-
related toxicity (inflammation-related alterations in drug
pharmacokinetic).
Data on CRPC are strongly significant and are ob-
tained in large populations from randomized trials. Dif-
ferent phase II and III trials [66–70] used OS and
clinical progression free survival as end-points to evalu-
ate the prognostic role of inflammatory variables
(Table 4).
Both NLR and CRP resulted independent and signifi-
cant predictors of OS and progression free survival in
CRPC cases during chemotherapy with Docetaxel and
for NLR also during abiraterone . An optimal threshold
of NLR for the prediction of OS was set at 2–3 whereas
of CRP at 8 [71].
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Externally validated prognostic algorithms, in patients
with metastatic CRPC considered for docetaxel, includ-
ing NLR or CRP have been proposed [66–70].
The results of these studies qualify the NLR as an in-
dependent predictor of mortality in CRPC patients and
support its incorporation in prognostic models to stratify
patients with CRPC.
Conclusions
The high prevalence of chronic inflammation in patho-
logical samples of prostate tissue from surgery or pros-
tate biopsy has sustained a possible link between
inflammation and PC. In cases with PC diagnosis, an
association with an inflammatory status may determine
a poorer prognosis, higher aggressiveness of the tumor
and lower response to therapies. These aspects have
been analyzed in several clinical trials; however the
majority of data are retrospective rather than prospect-
ive. Specific markers of prostatic inflammation have
not been significantly identified as possible prognostic
predictors.
On the contrary, most of data are focused on markers
of systemic inflammation. in particular NLR and CRP,
that can be easily obtained from the serum. Based on
multivariate analysis they resulted independent signifi-
cant predictors of clinical response to radiotherapy in lo-
calized and locally advanced PC or chemotherapy in
CRPC cases, also after adjustment for the other clinical
parameters. The suggestion is that these inflammatory
parameters, also if not specific for prostatic inflamma-
tion and possibly influenced by several factors other than
PC, can integrate with established prognostic factors.
Validated prognostic algorithms including NLR or
CRP have been proposed in particular for CRPC cases
but prospective clinical trials should confirm these
positive data.
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Systemic inflammation NLR [64] Phase III study on CRPC submitted
to docetaxel
NLR and risk of death 1.29 (1.11–1.50) <0.001
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